Needham & Company LLC Cuts Boston Scientific (NYSE:BSX) Price Target to $97.00

Boston Scientific (NYSE:BSX) had its price target lowered by Needham & Company LLC from $121.00 to $97.00 in a research note issued to investors on Thursday, MarketBeat Ratings reports. The brokerage currently has a buy rating on the medical equipment provider’s stock.

BSX has been the topic of a number of other research reports. Robert W. Baird dropped their price target on Boston Scientific from $118.00 to $101.00 and set an “outperform” rating on the stock in a research note on Thursday. TD Cowen dropped their target price on shares of Boston Scientific from $115.00 to $100.00 and set a “buy” rating on the stock in a research report on Monday, February 2nd. Oppenheimer cut their price target on shares of Boston Scientific from $125.00 to $100.00 and set an “outperform” rating on the stock in a research note on Friday, January 16th. National Bankshares set a $115.00 price objective on shares of Boston Scientific in a research note on Monday, February 2nd. Finally, Truist Financial cut their target price on Boston Scientific from $120.00 to $95.00 and set a “buy” rating on the stock in a research report on Thursday. One analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $109.43.

Boston Scientific Price Performance

NYSE BSX opened at $76.24 on Thursday. The firm’s fifty day simple moving average is $93.39 and its two-hundred day simple moving average is $98.75. The firm has a market capitalization of $113.02 billion, a P/E ratio of 39.30, a P/E/G ratio of 1.35 and a beta of 0.67. The company has a current ratio of 1.51, a quick ratio of 0.96 and a debt-to-equity ratio of 0.47. Boston Scientific has a 12-month low of $74.86 and a 12-month high of $109.50.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share for the quarter, topping analysts’ consensus estimates of $0.78 by $0.02. Boston Scientific had a return on equity of 19.96% and a net margin of 14.44%.The firm had revenue of $5.29 billion during the quarter, compared to analysts’ expectations of $5.29 billion. During the same quarter last year, the firm earned $0.70 EPS. The business’s quarterly revenue was up 15.9% on a year-over-year basis. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. Analysts forecast that Boston Scientific will post 2.85 EPS for the current fiscal year.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, CEO Michael F. Mahoney sold 160,901 shares of Boston Scientific stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the completion of the transaction, the chief executive officer owned 1,411,735 shares in the company, valued at approximately $131,983,105.15. This trade represents a 10.23% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Arthur C. Butcher sold 17,313 shares of the company’s stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $101.55, for a total value of $1,758,135.15. Following the completion of the sale, the executive vice president owned 23,600 shares in the company, valued at $2,396,580. The trade was a 42.32% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 0.50% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of BSX. Vanguard Group Inc. increased its holdings in shares of Boston Scientific by 1.0% during the 4th quarter. Vanguard Group Inc. now owns 139,685,997 shares of the medical equipment provider’s stock valued at $13,319,060,000 after purchasing an additional 1,436,550 shares in the last quarter. State Street Corp grew its position in Boston Scientific by 1.1% during the second quarter. State Street Corp now owns 65,191,864 shares of the medical equipment provider’s stock valued at $7,002,258,000 after buying an additional 713,379 shares during the period. Geode Capital Management LLC increased its holdings in Boston Scientific by 2.0% in the second quarter. Geode Capital Management LLC now owns 32,424,982 shares of the medical equipment provider’s stock valued at $3,466,320,000 after buying an additional 622,602 shares in the last quarter. Norges Bank acquired a new position in shares of Boston Scientific in the second quarter worth about $2,089,937,000. Finally, Invesco Ltd. raised its position in shares of Boston Scientific by 0.7% in the third quarter. Invesco Ltd. now owns 16,963,344 shares of the medical equipment provider’s stock worth $1,656,131,000 after acquiring an additional 111,826 shares during the period. 89.07% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Q4 beat but mixed outlook — Boston Scientific reported stronger-than-expected Q4 results (revenue growth and EPS beat), showing continued top-line momentum that supports the longer‑term growth story. Q4 results and presentation
• Positive Sentiment: Some analysts still rate BSX as a buy/overweight with mid‑to‑high price targets — several firms left positive ratings (Morgan Stanley set a $118 PT; others keep “outperform/overweight”), indicating continued analyst confidence in long-term upside despite near-term caution. Morgan Stanley PT note
• Neutral Sentiment: Board change announced — Boston Scientific disclosed a planned long‑serving director departure; governance turnover is notable but not currently flagged as material to near‑term operations. Board director departure
• Neutral Sentiment: Unusually active options and volume — options and share volume spiked during the sell‑off, increasing volatility and making short-term price moves more extreme (can amplify both down and up moves). Options activity
• Negative Sentiment: Cautious 2026 guidance and weak electrophysiology sales drove a sharp sell‑off — management’s conservative revenue/growth guidance and softer performance in a key segment prompted a high‑volume liquidation that erased recent gains. Guidance and segment weakness
• Negative Sentiment: Multiple securities‑fraud investigations announced — several law firms have opened inquiries into Boston Scientific’s disclosures around the quarter/guidance, increasing legal and reputational risk. Howard G. Smith investigation Frank R. Cruz investigation
• Negative Sentiment: Insider selling and new lows — CEO share sales and headlines about insider selling coincided with the stock reaching a 12‑month low, which can undermine investor confidence even when fundamentals are mixed. CEO stock sale note 12-month low report
• Negative Sentiment: Widespread analyst price‑target cuts — multiple firms trimmed their 12‑month targets after Q4/guidance, increasing short‑term downside pressure even where ratings remain constructive. Analyst cuts roundup

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.